Back to Search
Start Over
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
- Source :
- Annals of Oncology, 27(8), 1638-1643. Elsevier Ltd., Annals of Oncology, 27(8), 1638. Oxford University Press
- Publication Year :
- 2016
-
Abstract
- BACKGROUND:Early signs of efficacy are critical in drug development. Response Evaluation Criteria in Solid Tumors (RECIST) are commonly used to determine the efficacy of anti-cancer therapy in clinical trials. RECIST, however, emphasizes the value of tumor shrinkage, while many targeted agents induce prolonged tumor growth arrest. This limits its use for the detection of treatment efficacy for these more cytostatic regimens. Therefore, we designed an individualized variant of a time to progression (TTP) end point based on prospective volumetric measurements and an intra-patient control, the TTP ratio.PATIENTS AND METHODS:Patients with any metastatic malignancy, without regular treatment options, were treated with the mTOR inhibitor everolimus. Treatment response was determined using both RECIST and the TTP ratio. The TTP ratio was defined as the volumetric pretreatment TTP divided by the volumetric on-treatment TTP. A patient was classified as a responder if the TTP ratio was
- Subjects :
- Male
0301 basic medicine
Oncology
0302 clinical medicine
Stable Disease
Neoplasms
hemic and lymphatic diseases
heterocyclic compounds
Molecular Targeted Therapy
Medicine(all)
Hematology
Middle Aged
respiratory system
Treatment Outcome
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Disease Progression
Female
therapeutics
medicine.drug
Adult
medicine.medical_specialty
Efficacy
Time to progression ratio
Malignancy
RECIST 1.1
Disease-Free Survival
03 medical and health sciences
Internal medicine
medicine
Journal Article
Humans
Everolimus
Protein Kinase Inhibitors
neoplasms
Aged
business.industry
Cancer
medicine.disease
Confidence interval
Surgery
Clinical trial
Clinical trial end point
030104 developmental biology
Commentary
business
Subjects
Details
- ISSN :
- 09237534
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology, 27(8), 1638-1643. Elsevier Ltd., Annals of Oncology, 27(8), 1638. Oxford University Press
- Accession number :
- edsair.doi.dedup.....62fbbfdd4125e592d8a7943456c183e9